Sign up to save your podcasts
Or
Share Will ODYSSEY Clear Hurdles for PCSK9 Inhibitor Access?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Will ODYSSEY Clear Hurdles for PCSK9 Inhibitor Access?
Drs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.
View all episodes
By MedscapeDrs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.